Pfizer Profitability Analysis
| PFE Stock | USD 25.18 0.28 1.12% |
Net Income | First Reported 1985-09-30 | Previous Quarter 2.9 B | Current Value 3.5 B | Quarterly Volatility 2.4 B |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.81 | 0.76 |
|
| |||||
| Net Profit Margin | 0.14 | 0.11 |
|
| |||||
| Operating Profit Margin | 0.21 | 0.23 |
|
| |||||
| Pretax Profit Margin | 0.17 | 0.11 |
|
| |||||
| Return On Assets | 0.0411 | 0.0432 |
|
| |||||
| Return On Equity | 0.0993 | 0.1 |
|
|
For Pfizer profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Pfizer to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Pfizer Inc utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Pfizer's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Pfizer Inc over time as well as its relative position and ranking within its peers.
Check out Your Equity Center. Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.21) | Dividend Share 1.7 | Earnings Share 1.72 | Revenue Per Share | Quarterly Revenue Growth (0.06) |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Pfizer Inc Return On Asset vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Pfizer's current stock value. Our valuation model uses many indicators to compare Pfizer value to that of its competitors to determine the firm's financial worth. Pfizer Inc is regarded second in return on equity category among its peers. It is regarded fourth in return on asset category among its peers reporting about 0.49 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Pfizer Inc is roughly 2.04 . At present, Pfizer's Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Pfizer by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Pfizer Return On Asset vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Pfizer |
| = | 0.11 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Pfizer |
| = | 0.0519 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Pfizer Return On Asset Comparison
Pfizer is currently under evaluation in return on asset category among its peers.
Pfizer Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Pfizer, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Pfizer will eventually generate negative long term returns. The profitability progress is the general direction of Pfizer's change in net profit over the period of time. It can combine multiple indicators of Pfizer, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -7.1 B | -7.4 B | |
| Operating Income | 19 B | 11.1 B | |
| Income Before Tax | 9.2 B | 8.6 B | |
| Total Other Income Expense Net | -7.6 B | -7.2 B | |
| Net Income | 9.3 B | 9.3 B | |
| Income Tax Expense | -32.2 M | -30.6 M | |
| Net Income Applicable To Common Shares | 9.2 B | 12.2 B | |
| Net Income From Continuing Ops | 9.3 B | 13.1 B | |
| Non Operating Income Net Other | -249.6 M | -262 M | |
| Interest Income | 626.8 M | 891.9 M | |
| Net Interest Income | -2.3 B | -2.2 B | |
| Change To Netincome | -2.5 B | -2.3 B | |
| Net Income Per Share | 1.27 | 0.94 | |
| Income Quality | 1.42 | 1.18 | |
| Net Income Per E B T | 0.90 | 0.70 |
Pfizer Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Pfizer. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Pfizer position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Pfizer's important profitability drivers and their relationship over time.
Pfizer Profitability Trends
Pfizer profitability trend refers to the progression of profit or loss within a business. An upward trend means that Pfizer's profit has generally increased over time, and a downward profitability trend means profits are declining. Recognizing problems early in profitability trends allows investors to address revenue and cost issues in advance. Investors and analysts usually monitor three types of profitability trends: gross, operating, and net. Gross profit is the difference between revenue and costs of goods sold. Operating profit is Pfizer's gross profit minus its overhead. After you account for other unusual revenue, expenses, and costs, you get net profit. Gross profit trends are often a good indicator of future profitability. If you have high gross profit margins, you have a better chance to cover overhead and make money.
Pfizer Profitability Drivers Correlations
One of the toughest challenges investors face today is learning how to quickly synthesize and read into endless financial statements and information provided by the company, SEC reporting, and various external parties. Understanding the correlation between Pfizer different financial indicators related to revenue and profit generation helps investors identify and prioritize their investing strategies towards Pfizer in a much-optimized way. Analyzing correlations between profit drivers that are directly associated with dollar figures is the most effective way to break down Pfizer's future profitability.
Click cells to compare fundamentals
Pfizer Earnings Estimation Breakdown
The calculation of Pfizer's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Pfizer is estimated to be 0.56 with the future projection ranging from a low of 0.75 to a high of 0.81. Please be aware that this consensus of annual earnings estimates for Pfizer Inc is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.75 Lowest | Expected EPS | 0.81 Highest |
Pfizer Earnings Projection Consensus
Suppose the current estimates of Pfizer's value are higher than the current market price of the Pfizer stock. In this case, investors may conclude that Pfizer is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Pfizer's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 26 | 74.29% | 0.87 | 0.56 | 1.72 |
Pfizer Earnings History
Earnings estimate consensus by Pfizer Inc analysts from Wall Street is used by the market to judge Pfizer's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Pfizer's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Pfizer Quarterly Gross Profit |
|
Pfizer Earnings per Share Projection vs Actual
Actual Earning per Share of Pfizer refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Pfizer Inc predict the company's earnings will be in the future. The higher the earnings per share of Pfizer, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Pfizer Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Pfizer, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Pfizer should always be considered in relation to other companies to make a more educated investment decision.Pfizer Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Pfizer's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-11-04 | 2025-09-30 | 0.63 | 0.87 | 0.24 | 38 | ||
2025-08-05 | 2025-06-30 | 0.36 | 0.51 | 0.15 | 41 | ||
2025-04-29 | 2025-03-31 | 0.67 | 0.92 | 0.25 | 37 | ||
2025-02-04 | 2024-12-31 | 0.46 | 0.63 | 0.17 | 36 | ||
2024-10-29 | 2024-09-30 | 0.61 | 1.06 | 0.45 | 73 | ||
2024-07-30 | 2024-06-30 | 0.46 | 0.6 | 0.14 | 30 | ||
2024-05-01 | 2024-03-31 | 0.34 | 0.55 | 0.21 | 61 | ||
2024-01-30 | 2023-12-31 | -0.18 | 0.1 | 0.28 | 155 | ||
2023-10-31 | 2023-09-30 | -0.5 | -0.42 | 0.08 | 16 | ||
2023-08-01 | 2023-06-30 | 0.58 | 0.67 | 0.09 | 15 | ||
2023-05-02 | 2023-03-31 | 0.99 | 1.23 | 0.24 | 24 | ||
2023-01-31 | 2022-12-31 | 1.04 | 1.14 | 0.1 | 9 | ||
2022-11-01 | 2022-09-30 | 1.4 | 1.78 | 0.38 | 27 | ||
2022-07-28 | 2022-06-30 | 1.78 | 2.04 | 0.26 | 14 | ||
2022-05-03 | 2022-03-31 | 1.57 | 1.62 | 0.05 | 3 | ||
2022-02-08 | 2021-12-31 | 0.87 | 1.08 | 0.21 | 24 | ||
2021-11-02 | 2021-09-30 | 1.09 | 1.34 | 0.25 | 22 | ||
2021-07-28 | 2021-06-30 | 0.98 | 1.07 | 0.09 | 9 | ||
2021-05-04 | 2021-03-31 | 0.78 | 0.93 | 0.15 | 19 | ||
2021-02-02 | 2020-12-31 | 0.46 | 0.42 | -0.04 | 8 | ||
2020-10-27 | 2020-09-30 | 0.71 | 0.72 | 0.01 | 1 | ||
2020-07-28 | 2020-06-30 | 0.66 | 0.78 | 0.12 | 18 | ||
2020-04-28 | 2020-03-31 | 0.73 | 0.8 | 0.07 | 9 | ||
2020-01-28 | 2019-12-31 | 0.58 | 0.55 | -0.03 | 5 | ||
2019-10-29 | 2019-09-30 | 0.62 | 0.75 | 0.13 | 20 | ||
2019-07-29 | 2019-06-30 | 0.75 | 0.8 | 0.05 | 6 | ||
2019-04-30 | 2019-03-31 | 0.75 | 0.85 | 0.1 | 13 | ||
2019-01-29 | 2018-12-31 | 0.63 | 0.64 | 0.01 | 1 | ||
2018-10-30 | 2018-09-30 | 0.75 | 0.78 | 0.03 | 4 | ||
2018-07-31 | 2018-06-30 | 0.74 | 0.81 | 0.07 | 9 | ||
2018-05-01 | 2018-03-31 | 0.74 | 0.77 | 0.03 | 4 | ||
2018-01-30 | 2017-12-31 | 0.56 | 0.62 | 0.06 | 10 | ||
2017-10-31 | 2017-09-30 | 0.65 | 0.67 | 0.02 | 3 | ||
2017-08-01 | 2017-06-30 | 0.66 | 0.67 | 0.01 | 1 | ||
2017-05-02 | 2017-03-31 | 0.67 | 0.69 | 0.02 | 2 | ||
2017-01-31 | 2016-12-31 | 0.51 | 0.47 | -0.04 | 7 | ||
2016-11-01 | 2016-09-30 | 0.62 | 0.61 | -0.01 | 1 | ||
2016-08-02 | 2016-06-30 | 0.62 | 0.64 | 0.02 | 3 | ||
2016-05-03 | 2016-03-31 | 0.55 | 0.67 | 0.12 | 21 | ||
2016-02-02 | 2015-12-31 | 0.52 | 0.53 | 0.01 | 1 | ||
2015-10-27 | 2015-09-30 | 0.51 | 0.6 | 0.09 | 17 | ||
2015-07-28 | 2015-06-30 | 0.52 | 0.56 | 0.04 | 7 | ||
2015-04-28 | 2015-03-31 | 0.49 | 0.51 | 0.02 | 4 | ||
2015-01-27 | 2014-12-31 | 0.53 | 0.54 | 0.01 | 1 | ||
2014-10-28 | 2014-09-30 | 0.55 | 0.57 | 0.02 | 3 | ||
2014-07-29 | 2014-06-30 | 0.57 | 0.58 | 0.01 | 1 | ||
2014-05-05 | 2014-03-31 | 0.55 | 0.57 | 0.02 | 3 | ||
2014-01-28 | 2013-12-31 | 0.53 | 0.56 | 0.03 | 5 | ||
2013-10-29 | 2013-09-30 | 0.56 | 0.58 | 0.02 | 3 | ||
2013-07-30 | 2013-06-30 | 0.55 | 0.56 | 0.01 | 1 | ||
2013-04-30 | 2013-03-31 | 0.55 | 0.54 | -0.01 | 1 | ||
2013-01-29 | 2012-12-31 | 0.44 | 0.47 | 0.03 | 6 | ||
2012-11-01 | 2012-09-30 | 0.52 | 0.53 | 0.01 | 1 | ||
2012-07-31 | 2012-06-30 | 0.55 | 0.62 | 0.07 | 12 | ||
2012-05-01 | 2012-03-31 | 0.57 | 0.58 | 0.01 | 1 | ||
2012-01-31 | 2011-12-31 | 0.47 | 0.5 | 0.03 | 6 | ||
2011-11-01 | 2011-09-30 | 0.56 | 0.62 | 0.06 | 10 | ||
2011-08-02 | 2011-06-30 | 0.59 | 0.6 | 0.01 | 1 | ||
2011-05-03 | 2011-03-31 | 0.58 | 0.6 | 0.02 | 3 | ||
2011-02-01 | 2010-12-31 | 0.46 | 0.47 | 0.01 | 2 | ||
2010-11-02 | 2010-09-30 | 0.51 | 0.54 | 0.03 | 5 | ||
2010-08-03 | 2010-06-30 | 0.52 | 0.62 | 0.1 | 19 | ||
2010-05-04 | 2010-03-31 | 0.24 | 0.25 | 0.01 | 4 | ||
2010-02-03 | 2009-12-31 | 0.51 | 0.49 | -0.02 | 3 | ||
2009-10-20 | 2009-09-30 | 0.48 | 0.51 | 0.03 | 6 | ||
2009-07-22 | 2009-06-30 | 0.46 | 0.48 | 0.02 | 4 | ||
2009-04-28 | 2009-03-31 | 0.49 | 0.54 | 0.05 | 10 | ||
2009-01-26 | 2008-12-31 | 0.6 | 0.64 | 0.04 | 6 | ||
2008-10-21 | 2008-09-30 | 0.6 | 0.62 | 0.02 | 3 | ||
2008-07-23 | 2008-06-30 | 0.54 | 0.55 | 0.01 | 1 | ||
2008-04-17 | 2008-03-31 | 0.65 | 0.61 | -0.04 | 6 | ||
2008-01-23 | 2007-12-31 | 0.47 | 0.52 | 0.05 | 10 | ||
2007-10-18 | 2007-09-30 | 0.52 | 0.58 | 0.06 | 11 | ||
2007-07-18 | 2007-06-30 | 0.5 | 0.42 | -0.08 | 16 | ||
2007-04-20 | 2007-03-31 | 0.57 | 0.68 | 0.11 | 19 | ||
2007-01-22 | 2006-12-31 | 0.42 | 0.43 | 0.01 | 2 | ||
2006-10-19 | 2006-09-30 | 0.45 | 0.54 | 0.09 | 20 | ||
2006-07-20 | 2006-06-30 | 0.48 | 0.52 | 0.04 | 8 | ||
2006-04-19 | 2006-03-31 | 0.53 | 0.61 | 0.08 | 15 | ||
2006-01-19 | 2005-12-31 | 0.42 | 0.51 | 0.09 | 21 | ||
2005-10-20 | 2005-09-30 | 0.48 | 0.51 | 0.03 | 6 | ||
2005-07-20 | 2005-06-30 | 0.44 | 0.46 | 0.02 | 4 | ||
2005-04-19 | 2005-03-31 | 0.53 | 0.54 | 0.01 | 1 | ||
2005-01-19 | 2004-12-31 | 0.59 | 0.58 | -0.01 | 1 | ||
2004-10-20 | 2004-09-30 | 0.54 | 0.55 | 0.01 | 1 | ||
2004-07-21 | 2004-06-30 | 0.46 | 0.47 | 0.01 | 2 | ||
2004-04-20 | 2004-03-31 | 0.51 | 0.52 | 0.01 | 1 | ||
2004-01-22 | 2003-12-31 | 0.51 | 0.53 | 0.02 | 3 | ||
2003-10-22 | 2003-09-30 | 0.44 | 0.47 | 0.03 | 6 | ||
2003-07-25 | 2003-06-30 | 0.29 | 0.3 | 0.01 | 3 | ||
2003-04-22 | 2003-03-31 | 0.44 | 0.45 | 0.01 | 2 | ||
2003-01-22 | 2002-12-31 | 0.47 | 0.48 | 0.01 | 2 | ||
2002-10-16 | 2002-09-30 | 0.38 | 0.39 | 0.01 | 2 | ||
2002-07-15 | 2002-06-30 | 0.32 | 0.33 | 0.01 | 3 | ||
2002-04-17 | 2002-03-31 | 0.39 | 0.39 | 0.0 | 0 | ||
2002-01-23 | 2001-12-31 | 0.34 | 0.34 | 0.0 | 0 | ||
2001-10-17 | 2001-09-30 | 0.33 | 0.34 | 0.01 | 3 | ||
2001-07-17 | 2001-06-30 | 0.3 | 0.3 | 0.0 | 0 | ||
2001-04-18 | 2001-03-31 | 0.31 | 0.33 | 0.02 | 6 | ||
2001-01-24 | 2000-12-31 | 0.27 | 0.27 | 0.0 | 0 | ||
2000-10-24 | 2000-09-30 | 0.25 | 0.27 | 0.02 | 8 | ||
2000-07-24 | 2000-06-30 | 0.22 | 0.23 | 0.01 | 4 | ||
2000-04-18 | 2000-03-31 | 0.25 | 0.28 | 0.03 | 12 | ||
2000-01-18 | 1999-12-31 | 0.23 | 0.25 | 0.02 | 8 | ||
1999-10-19 | 1999-09-30 | 0.21 | 0.23 | 0.02 | 9 | ||
1999-07-19 | 1999-06-30 | 0.17 | 0.19 | 0.02 | 11 | ||
1999-04-15 | 1999-03-31 | 0.21 | 0.21 | 0.0 | 0 | ||
1999-01-19 | 1998-12-31 | 0.17 | 0.18 | 0.01 | 5 | ||
1998-10-13 | 1998-09-30 | 0.19 | 0.17 | -0.02 | 10 | ||
1998-07-09 | 1998-06-30 | 0.15 | 0.17 | 0.02 | 13 | ||
1998-04-14 | 1998-03-31 | 0.18 | 0.18 | 0.0 | 0 | ||
1998-01-20 | 1997-12-31 | 0.14 | 0.14 | 0.0 | 0 | ||
1997-10-14 | 1997-09-30 | 0.15 | 0.15 | 0.0 | 0 | ||
1997-07-15 | 1997-06-30 | 0.12 | 0.12 | 0.0 | 0 | ||
1997-04-15 | 1997-03-31 | 0.16 | 0.16 | 0.0 | 0 | ||
1997-01-16 | 1996-12-31 | 0.13 | 0.13 | 0.0 | 0 | ||
1996-10-14 | 1996-09-30 | 0.13 | 0.13 | 0.0 | 0 | ||
1996-07-17 | 1996-06-30 | 0.1 | 0.1 | 0.0 | 0 | ||
1996-04-16 | 1996-03-31 | 0.13 | 0.14 | 0.01 | 7 | ||
1996-01-17 | 1995-12-31 | 0.11 | 0.11 | 0.0 | 0 | ||
1995-10-15 | 1995-09-30 | 0.11 | 0.11 | 0.0 | 0 |
Use Pfizer in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pfizer position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pfizer will appreciate offsetting losses from the drop in the long position's value.Pfizer Pair Trading
Pfizer Inc Pair Trading Analysis
The ability to find closely correlated positions to Pfizer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pfizer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pfizer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pfizer Inc to buy it.
The correlation of Pfizer is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pfizer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pfizer Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pfizer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Pfizer position
In addition to having Pfizer in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Munis Funds Thematic Idea Now
Munis Funds
Funds or Etfs that invest in fixed income securities issued by states, cities, and towns as well as other public entities. The Munis Funds theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Munis Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
To fully project Pfizer's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Pfizer Inc at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Pfizer's income statement, its balance sheet, and the statement of cash flows.